Media Releases
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
April 29, 2021
FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for...
AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy
January 04, 2021
Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall. MASON, Ohio --(BUSINESS WIRE)--Jan. 4, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial...